Overview

This trial is active, not recruiting.

Conditions osteoarthritis, knee, knee degenerative disease, knee osteoarthritis
Treatment autologous bone marrow mesenchymal stem cells (msv)
Phase phase 1/phase 2
Sponsor Red de Terapia Celular
Collaborator Fundacion Teknon, Centro Medico Teknon, Barcelona
Start date May 2010
End date August 2014
Trial size 12 participants
Trial identifier NCT01183728, Eudra-CT 2009-017405-11, Protocol Code, TerCel001

Summary

In this prospective study we aim to evaluate the feasibility and safety of the implantation of 40 millions MSV in knees with osteoarthritis of grade II-IV (Kellgren and Lawrence). The working hypothesis proposes that MSV antiinflammatory effect will help healing of articular cartilage degeneration to a grade enough to be objectivized by questionnaires and imaging procedures. The study of quantitative changes in structure and composition of cartilage determined by T2-weighted MRI (Cartigram ) will be performed at 6, 12 and 24 months. Pain will be assessed by visual analogue scale (VAS), Oswestry disability index and evaluation of the quality of life by Short Form 36 questionnaire (SF-36) completed at 3, 6,12 and 24 months.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection
autologous bone marrow mesenchymal stem cells (msv) MSV, mesenchymal stem cells by IBGM-Valladolid protocol.
Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.

Primary Outcomes

Measure
To evaluate the feasibility and safety of the implementation of MSV in the treatment of osteoarthritis of the knee.
time frame: 0, 3, 6, 12 and 24 months

Secondary Outcomes

Measure
Indication of efficacy
time frame: 0, 3, 6, 12, 24 months

Eligibility Criteria

Male or female participants from 18 years up to 76 years old.

Inclusion Criteria: - Knee osteoarthritis grade II, III and IV of Kellgren and Lawrence assessed by two observers. - Chronic knee pain with mechanical characteristics. - No local or systemic septic process. - Haematological and biochemical analysis without significant alterations that contraindicate treatment. - Informed written consent of the patient. - The patient is able to understand the nature of the study Exclusion Criteria: - Age over 75 or under 18 years or legally dependent - Any sign of infection - Positive serology for HIV-1 orHIV-2, Hepatitis B (HBsAg, Anti-HCV-Ab), Hepatitis C (Anti-HCV-Ab) and syphilis. - Congenital or acquired malformation resulting in significant deformity of the knee and leading to problems in application or evaluation of results. - Overweight expressed as body mass index (BMI) greater than 30.5 (obesity grade II). BMI estimated as mass (kg) / corporal surface (m2). - Women who are pregnant or intend to become pregnant or breast-feeding - Neoplasia - Immunosuppressive states - Participation in another clinical trial or treatment with a different investigational product within 30 days prior to inclusion in the study. - Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria

Additional Information

Official title Regeneration of Articular Cartilage in Grade II, III and IV Knee Osteoarthritis by Intraarticular Injection of Autologous Bone Marrow Stem Cells Expanded ex Vivo With a GMP Procedure Developed by IBGM-Valladolid (MSV)
Principal investigator Luis Orozco, MD, PhD
Description Knee osteoarthritis is the most common form of arthritis. Treatments involve high costs in terms of social and economic, are palliative and do not contemplate healing by regenerative therapy. It has been shown recently, that mesenchymal stem cells (MSC) can be expanded "in vitro" and may regenerate several damaged or injured tissues. In addition its has demonstrated that MSC are able to modulate immune responses and to control inflammation through its action on T lymphocytes. Preliminary studies in animal models, including one carried out in an equine by our research group, confirms feasibility, safety and efficacy evidence proposed treatment protocol. Our research group has also experience in preparing clinical-grade MSC from bone marrow for other clinical trials and has all the necessary facilities and permissions to comply with GMPs imposed by recent EU legislation. Finally, our clinical team has a wide experience in regenerative therapies in several previous clinical trials for bone and cartilage. We present here an alternative proposal, aiming to anti-inflamación and regeneration by injection of single dose of mesenchymal stem cells expanded from autologous bone marrow by the GMP-complying IBGM-Valladolid procedure (MSV). Treatment involves two non-invasive surgical procedures with low morbidity: obtaining bone marrow under local anesthesia and sedation, and 4 weeks later, articular injection of the cell product (20 millions MSVs). The injection of cells does not even require anesthesia and obtaining bone marrow requires an outpatient admission two hours following safety criteria. Patients will be evaluated clinically, including pain score (VSA), disability index (Oswestry) and life quality (SF-36), and by radiologic and MRI procedures no contrast and allowing quantification of morphological and structural changes of the cartilage region studied (T2-weighted imaging). The design of the study is an open-label prospective, multicenter study. It will recruit 12 patients with osteoarthritis of II-IV Kellgren and Lawrence grades, Patients will be evaluated clinically by previous studies imaging (X-rays and MRI). If they are eligible for the study we shall provide them information about the clinical trial with the "Patient Information Sheet, quoting them for the Inclusion Visit. In the "Inclusion Visit" if the patient decides to participate in the test should sign the Informed Consent Document and a schedule for MRI and X-rays will be scheduled. The results of this exploration will be considered the standard to which compare any given change in the controls at 6 and 12 months. On this visit, routine preoperative examinations are performed (EKG, chest X-ray AP, basic analytic coagulation tests and identification of HIV, Lues and hepatitis B and C and the valuation by the Internal Medicine Service). During the visit V0 we shall verify that all inclusion criteria persist and not exclusion criteria have appeared, and we shall program V1 (to obtain bone marrow) and provide a preliminary date for MSV injection 4 week later (V2). After application, the patients will have follow-up schedule at 8 days (V3), 3 (V4), 6 (V5), 12 (V6) and eventually 24 months (V7) as detailed below. V0: Eligibility. Clinical History. Analysis, Imaging test. Programming of the following visits V1 (day 0): Bone marrow aspiration under local anesthesia and sedation V2 (day 23). MSV Implantation. V3 (+8 days from Implantation): Security evaluation. V4 (+3 months from Implantation): Security evaluation. VAS, ODI, SF-36 questionnaires. V5 (+6 months from Implantation): Security evaluation. VAS, ODI, SF-36 questionnaires, RX, RNM. V6 (+12 months from Implantation): Security evaluation. VAS, ODI, SF-36 questionnaires, RX, RNM. V7 (+24 months from Implantation): Security evaluation. VAS, ODI, SF-36 questionnaires, RX, RNM.
Trial information was received from ClinicalTrials.gov and was last updated in June 2014.
Information provided to ClinicalTrials.gov by Red de Terapia Celular.